

CONVOCAATION OF THE ANNUAL GENERAL MEETING OF REDCARE PHARMACY N.V. TO BE HELD PHYSICALLY AND VIRTUALLY ON 15 MAY 2025

Redcare Pharmacy N.V. (the "**Company**"), a public limited liability company incorporated and existing under the laws of The Netherlands, hereby invites its shareholders to attend the 2025 annual general meeting of the Company ("**2025 AGM**") to be held on Thursday, 15 May 2025 at 10:00 CEST. The 2025 AGM will be a hybrid meeting, meaning that shareholders are invited to attend the meeting either physically or virtually.

This convocation notice is divided into three sections:

Section A. Agenda

Section B. Explanatory notes to the agenda

Section C. General information and instructions on how to attend the 2025 AGM

This convocation notice has to be read in conjunction with the following documents, which are attached hereto:

- Annual report (including financial statements and sustainability statements) for the financial year 2024
- Proposed amendments of the articles of association of the Company in the form of a triptych containing the verbatim text (in Dutch and with an English office translation), together with an explanation to the proposed amendments
- Hybrid Meetings Policy

Redcare Pharmacy N.V.

The Managing Board

2 April 2025



Section A. AGENDA

1. Opening

2. 2024 Report of the Managing Board

- a. Report of the Managing Board (including sustainability statements) regarding the financial year 2024 (*discussion item*)
- b. Remuneration report for the financial year 2024 (*advisory voting item*)

3. 2024 Financial Statements

Adoption of the financial statements for the financial year 2024 (*voting item*)

4. Discharge

- a. Discharge from liability of all members of the Managing Board for the performance of their duties during the past financial year (*voting item*)
- b. Discharge from liability of all members of the Supervisory Board for the performance of their duties during the past financial year (*voting item*)

5. Re-appointment of the external auditor

- a. Re-appointment of Forvis Mazars Accountants N.V. as external auditor of the Company to audit the financial statements of the Company for the financial year ending 31 December 2025 (*voting item*)
- b. Appointment of Forvis Mazars Accountants N.V. as external auditor of the Company to perform a limited assurance audit on the sustainability statements of the Company for the financial year ending on 31 December 2025 (*voting item*)

6. Composition of the Supervisory Board

- a. Re-appointment of Mr. Jérôme Cochet as a member of the Supervisory Board for an additional term of one year (*voting item*)
- b. Appointment of Mr. Michael Köhler as a member of the Supervisory Board for a term of four years (*voting item*)
- c. Appointment of Mr. Stephan Weber as a member of the Supervisory Board for a term of four years (*voting item*)

7. Designation regarding the issue of (rights to acquire) shares

Designation of the Managing Board as the corporate body authorised to issue shares or to grant rights to subscribe for shares under, pursuant to and in connection with the 2019 ESOP for the calendar year 2025 and to restrict or exclude pre-emptive rights (*voting item*)

8. Authorisation to acquire own shares

Authorisation of the Managing Board to repurchase shares in the Company's own share capital up to a maximum of 10% for a period of 18 months (*voting item*)

9. Amendment of the Company's Articles of Association

Amendment of the Company's Articles of Association implementing the Dutch statutory large company regime and certain other changes (*voting item*)

10. Questions and any other business

11. Closing



Section B. EXPLANATORY NOTES TO THE AGENDA

Agenda item 1: Opening

Agenda item 2.a.: Report of the Managing Board (including the sustainability statements) regarding the financial year 2024 (*discussion item*)

The managing board of the Company (the "**Managing Board**") will first give a presentation regarding the performance of the Company in 2024 as presented and described in the financial statements and in the report of the Managing Board (including the sustainability statements) for the financial year 2024.

Forvis Mazars Accountants N.V. has audited the financial statements for the financial year 2024 and has issued an unqualified auditor's opinion thereon. Forvis Mazars Accountants N.V. also performed an assurance audit on the sustainability statements and has provided limited assurance thereon.

The shareholders will then be invited to discuss the financial statements and the report of the Managing Board for the financial year 2024.

Under this agenda item shareholders may also ask questions regarding the report of the Supervisory Board of the Company (the "**Supervisory Board**") as included in the annual report for the financial year 2024.

Agenda item 2.b.: Remuneration report for the financial year 2024 (*advisory voting item*)

The Supervisory Board has drawn up the Company's remuneration report for the financial year 2024. The remuneration report is submitted to the shareholders for a non-binding advisory vote in accordance with Section 2:135b subsection 2 of the Dutch Civil Code. It is proposed to approve the remuneration report for the financial year 2024.

To enable the advisory vote, the Supervisory Board will elaborate on the 2024 remuneration report that is included in the Company's annual report for the financial year 2024. Thereafter, the shareholders will be invited to share their views regarding the Company's remuneration report and the Company's implementation of the remuneration policy for the members of the Managing Board (the "**MB Remuneration Policy**") and the remuneration policy for the members of the Supervisory Board (the "**SB Remuneration Policy**") and together with the MB Remuneration Policy, the "**Remuneration Policy**").

In the remuneration report for the financial year 2024, it is explained how the advisory vote of the general meeting at the 2024 AGM has been considered.



Agenda item 3: Adoption of the financial statements for the financial year 2024 (*voting item*)

The Company's financial statements for the financial year 2024 were drawn up by the Managing Board and signed by the members of the Managing Board and the Supervisory Board.

The financial statements for the financial year 2024 were published on 11 March 2025 and are submitted for adoption by the general meeting in the 2025 AGM. It is proposed to adopt the financial statements for the financial year 2024.

Agenda item 4.a.: Discharge from liability of all members of the Managing Board for the performance of their duties during the past financial year (*voting item*)

It is proposed to grant discharge to all members of the Managing Board from liability for the performance of their duties during the financial year 2024, insofar as the performance of such duties is disclosed in the financial statements for the financial year 2024 or has otherwise been disclosed to the general meeting prior to the adoption of the financial statements for the financial year 2024.

Agenda item 4.b.: Discharge from liability of all members of the Supervisory Board for the performance of their duties during the past financial year (*voting item*)

It is also proposed to grant discharge to all members of the Supervisory Board from liability for the performance of their duties during the financial year 2024, insofar as the performance of such duties is disclosed in the financial statements for the financial year 2024 or has otherwise been disclosed to the general meeting prior to the adoption of the financial statements for the financial year 2024.

Agenda item 5.a.: Re-appointment of Forvis Mazars Accountants N.V. as external auditor of the Company to audit the financial statements of the Company for the financial year ending 31 December 2025 (*voting item*)

It is proposed to re-appoint Forvis Mazars Accountants N.V. (formerly named: Mazars Accountants N.V.) as the external auditor of the Company to audit the financial statements of the Company for the financial year ending 31 December 2025.



Agenda item 5b.: Appointment of Forvis Mazars Accountants N.V. as external auditor of the Company to perform a limited assurance audit on the sustainability reporting of the Company for the financial year ending on 31 December 2025 (voting item)

In anticipation of the transposition of the EU Corporate Sustainability Reporting Directive ("CSRD") into Dutch law and subject to the Dutch CSRD implementation bill taking effect for the financial year 2025, it is proposed to appoint Forvis Mazars Accountants N.V. as external auditor of the Company to perform a limited assurance audit on the sustainability report of the Company for the financial year ending on 31 December 2025.

Agenda item 6.a.: Re-appointment of Mr. Jérôme Cochet as member of the Supervisory Board for an additional term of one year (voting item)

In accordance with article 20 of the Company's articles of association, and by way of a non-binding nomination of the Supervisory Board, it is proposed to the general meeting to extend the term of re-appointment of Mr. Cochet as member of the Supervisory Board with a term of one year, with effect as per the date of the 2025 AGM (i.e. 15 May 2025) and ending at the close of the annual general meeting to be held in 2026. Subject to his re-appointment, Mr. Cochet will continue to serve as Chair of the Remuneration Committee.

Mr. Jérôme Cochet – curriculum vitae

Age:	46
Profession:	Economist
Number of shares held in the Company:	2,217
Relevant work experience:	<ul style="list-style-type: none">▪ Senior Corporate Auditor at Bombardier 2004 - 2006▪ Engagement Manager at McKinsey & Company 2007 - 2011▪ Chief Sales and Marketing Officer at Zalando 2011 - 2018▪ Global Managing Director at Dunhumby 2018 - 2021▪ Co-Founder and Managing Director at GoodCarbon 2022 - present
Experience as a supervisory director:	<ul style="list-style-type: none">▪ Redcare Pharmacy N.V. 2016 – present

Mr. Cochet has been a member of the Supervisory Board since 2016. The proposed re-appointment of Mr. Cochet to the Supervisory Board is in accordance with the Company's articles of association and complies with the provisions of Section 2:142a of the Dutch Civil Code limiting the number of supervisory positions that may be held by supervisory board members of certain large companies. Mr. Cochet is considered independent within the meaning of the Dutch Corporate Governance Code.



The Supervisory Board has considered the contribution and performance of Mr. Cochet during his previous terms in office and is of the view that he has demonstrated a high level of commitment and expertise in his role as a member of the Supervisory Board. In addition, the Supervisory Board's nomination is motivated by a desire to maintain the expertise and knowledge that Mr. Cochet has accumulated while performing his current duties.

The nomination is supported by the Dutch Works Council of the Company. Subject to his re-appointment, the Supervisory Board Remuneration Policy will continue to apply to Mr. Cochet.

Agenda item 6.b.: Appointment of Mr. Michael Köhler as a member of the Supervisory Board for a term of four years (voting item)

In accordance with article 20 of the Company's articles of association, and by way of non-binding nomination of the Supervisory Board, it is proposed to the general meeting to appoint Mr. Köhler as a member of the Supervisory Board with effect as per the date of this General Meeting (i.e. 15 May 2025). The proposed appointment is for a four-year term ending at the close of the annual general meeting to be held in 2029.

Mr. Michael Köhler – curriculum vitae

Age:	62
Profession:	Private investor
Number of shares held in the Company:	284,840
Relevant work experience:	<ul style="list-style-type: none">▪ Various commercial, controlling and M&A/business development functions at Hoechst and Aventis (now Sanofi) < 2001▪ Founder and CEO of Europa Apotheek 2001 – 2016▪ CEO and member of the Managing Board of Shop Apotheke Europe N.V. (now Redcare Pharmacy N.V.) 2016 – 2018▪ Advisory Board of ZAVA (Health Bridge Limited) 2020 - present

Mr. Köhler will bring his strategic mindset as well as his extensive Rx online pharmacy and pharma industry expertise to the Supervisory Board. He shaped the Company from the very beginning and is deeply familiar with its culture and DNA. Mr. Köhler will be an invaluable asset in further developing the long-term strategy of the Company.

The proposed appointment of Mr. Köhler to the Supervisory Board is in accordance with the Company's articles of association and complies with the provisions of Section 2:142a of the Dutch Civil Code limiting the number of supervisory positions that may be held by supervisory board members of certain large companies.

Mr. Köhler is considered independent within the meaning of the Dutch Corporate Governance Code.



The appointment of Mr. Köhler, in combination with the envisaged appointment under agenda item 6.c, does not contribute to the target figures for the Supervisory Board set by the Company that 40% of the members of the Supervisory Board is female; though, the Company envisages that future appointments will contribute to such target figures.

The nomination is supported by the Dutch Works Council of the Company, and upon his appointment, Mr. Köhler will be considered the representative of the Dutch Works Council for the duration of his first four-year term of the Company, for which the Dutch Works Council has used its enhanced recommendation right in accordance with article 21.4 of the amended articles of associations (see voting item 9 Amendment Articles of Association).

Subject to his appointment, the Supervisory Board Remuneration Policy will apply to Mr. Köhler.

Agenda item 6.c.: Appointment of Mr. Stephan Weber as a member of the Supervisory Board for a term of four years (voting item)

In accordance with article 20 of the Company's articles of association, and by way of non-binding nomination of the Supervisory Board, it is proposed to the general meeting to appoint Mr. Weber as a member of the Supervisory Board with effect as per the date of this General Meeting (i.e. 15 May 2025). The proposed appointment is for a four-year term ending at the close of the annual general meeting to be held in 2029.

Mr. Stephan Weber – curriculum vitae

Age:	46
Profession:	Entrepreneur, Private Investor
Number of shares held in the Company:	52,329 shares and 40,000 stock options
Relevant work experience:	<ul style="list-style-type: none">▪ CCO of Shop Apotheke 2001 - 2016▪ CCO and member of the Managing Board of Shop Apotheke Europe N.V. (now Redcare Pharmacy N.V.) 2016 - 2024
Experience as a supervisory director:	<ul style="list-style-type: none">▪ MediService AG, Switzerland 2023 - 2024

Mr. Weber will bring his entrepreneurial spirit as well as his considerable industry knowledge to the Supervisory Board. He shaped the Company from the very beginning and is deeply familiar with its culture and DNA. With his proven track record in the scaling of e-commerce initiatives, Mr. Weber will be an ideal addition to help drive the Company's next growth phase.

The proposed appointment of Mr. Weber to the Supervisory Board is in accordance with the Company's articles of association and complies with the provisions of Section 2:142a of the Dutch Civil Code limiting the number of supervisory positions that may be held by supervisory board members of certain large companies.



Mr Weber is not considered independent within the meaning of the Dutch Corporate Governance Code as he has been a member of the Managing Board of the Company from 2016 until April 2024.

Reference is made to the explanation under agenda item 6.b in respect of the Company's target figures.

The nomination is supported by the Dutch Works Council of the Company.

The advisory agreement concluded on 17 April 2024 to retain the expertise of Mr. Weber for the Company, is terminated upon the approval of this agenda item. Subject to his appointment, the Supervisory Board Remuneration Policy will apply to Mr. Weber.

Agenda item 7.: Designation of the Managing Board as the corporate body authorised to issue shares and to grant rights to subscribe for shares under, pursuant to and in connection with the 2019 ESOP for the calendar year 2025 and to restrict or exclude pre-emptive rights (*voting item*)

In 2019, an employee stock option plan was implemented pursuant to which certain employees of the Company can be issued shares or grant rights to subscribe for shares in the share capital of the Company (i.e. stock options) (the "**2019 ESOP**"). The 2019 ESOP was evaluated by the Managing Board and an amendment of the terms of the 2019 ESOP was, with the Supervisory Board's prior approval, adopted during the 2022 annual general meeting of the Company (i.e. on 14 April 2022).

It is proposed that the general meeting designates the Managing Board as the corporate body authorised to issue shares or grant rights to subscribe for shares and restrict or exclude pre-emptive rights of existing shareholders to the extent required, subject to the prior approval of the Supervisory Board, up to a maximum of 50,000 (rights to acquire) shares (i.e. approx. 0.24% of the total number of issued shares outstanding on the date of the 2025 AGM), for the calendar year 2025, under, pursuant to and in connection with the 2019 ESOP (as amended).

For the avoidance of doubt, the issue of shares or grant rights to subscribe for shares under this authorisation of the Managing Board in connection with the 2019 ESOP will not be deducted from the general authorisation to issue shares granted to the Managing Board pursuant to the resolution of the general meeting on 17 April 2024.

It is envisaged that further authorisation(s) will be proposed to be granted to the Managing Board at the next annual general meeting(s) to issue (rights to acquire) shares under, pursuant to and in connection with the 2019 ESOP (as amended).



Agenda item 8: Authorisation of the Managing Board to repurchase shares in the Company's own share capital up to a maximum of 10% for a period of 18 months (*voting item*)

It is proposed that the general meeting authorises the Managing Board to repurchase shares, on the stock exchange or otherwise, for a period of 18 months as from the date of the 2025 AGM (i.e. up to and including 14 November 2026), up to a maximum of 10% of the total number of issued shares outstanding on the date of the 2025 AGM, provided that the Company will not hold more shares in treasury than a maximum 10% of the issued and outstanding share capital at any given time. The repurchase can take place at a price between the nominal value of the shares and the weighted average price on the Xetra trading venue at the Frankfurt Stock Exchange for five trading days prior the day of purchase plus 10%. This price range enables the Company to adequately repurchase its own shares, also in volatile market conditions.

Agenda item 9: Amendment of the Company's Articles of Association (*voting item*)

An amendment of the articles of association is proposed by the Managing Board and has been approved by the Supervisory Board. The reason for the proposed amendment of the articles of association of the Company is the implementation of the full large company regime (*volledig structuurregime*) which is mandatorily applicable to the Company due to it meeting the relevant thresholds set by Dutch law. At the same time, certain outdated provisions from the articles of association will be updated in accordance with new legislation or, where necessary, with changed practice. The full text of the proposal for the amendment of the articles of association is annexed to these notes to the agenda in the form of a tryptich containing the verbatim text (in Dutch and with an English office translation), together with an explanation to the proposed amendments.

The proposal under this agenda item 9 also includes the authorisation to each member of the Managing Board and each civil-law notary (and deputy civil-law notary) and notarial assistant at Allen Overy Shearman Sterling LLP, Attorneys at Law, Civil-Law Notaries and Tax Consultants, in Amsterdam, The Netherlands to have the notarial deed that effects the amendment of the Articles of Association under this agenda item 9 executed.

Agenda item 10: Questions and any other business

Agenda item 11: Closing



Section C. GENERAL INFORMATION [not updated yet except for Record Date]

C.1. Hybrid meeting

The 2025 AGM will take place as a hybrid meeting. This means that the Company's shareholders, who are entitled to participate and exercise voting rights, can take part in the 2025 AGM either:

- a. in-person at Bilderberg Château Holtmühle, Kasteellaan 10, 5932 AG, Tegelen, municipality Venlo (the Netherlands); or
- b. via the online platform provided by the Company's service provider Better Orange IR & HV AG (such online platform, the "**Virtual AGM Platform**").

The requirements for registration for the 2025 AGM and the process regarding (virtual) voting and submitting questions are set forth below. The Company's hybrid meetings policy and the terms and conditions regarding virtual general meetings (available on the Virtual AGM Platform) apply to all shareholders who wish to attend, participate and vote at the meeting via the Virtual AGM Platform.

Recognizing the ongoing importance of promoting environmental sustainability and reducing carbon footprints, the Company has decided to organize the 2025 AGM as a hybrid meeting. This format allows shareholders the flexibility to participate either in-person or virtually, aligning with the Company's commitment to environmental responsibility.

C.2. Meeting documents

The agenda with the explanatory notes thereto and the related documents are available on the Company's corporate website in the section Investor Relations/Corporate Governance/Annual General Meeting 2025 as from today (click [here](#)). Copies of the aforementioned documents are also available to shareholders free of charge. If you wish to receive copies, please contact us via investors@redcare-pharmacy.com. These documents are also available for review by shareholders at the Company's offices at Erik de Rodeweg 11-13, 5975 WD Sevenum, The Netherlands.

C.3. Attendance and registration

Shareholders who wish to attend and vote at the 2025 AGM (either in-person or through the Virtual AGM Platform) must:

- be a shareholder on the Record Date (see paragraph C.4 below);
- have registered for the 2025 AGM (see paragraph C.5 below);
- have received a proof of registration for the 2025 AGM (see paragraph C.6); and
- have identified themselves (see paragraph C.7 for attendance through the Virtual AGM Platform and paragraph C.8 for attendance in-person).



C.4. Record Date

The Managing Board has determined that persons entitled to participate in, and vote at, the 2025 AGM on Thursday, 15 May 2025 will be those persons who, after all changes have been processed have these rights on **Thursday, 17 April 2025** (the "**Record Date**") **at 18:00 CEST** and are registered as such in one of the designated registers, provided that those persons have registered for the 2025 AGM in time in accordance with the provisions below.

C.5. Registration

Shareholders who wish to attend and/or exercise their voting right at the 2025 AGM are required to notify Better Orange IR & HV AG by email redcare-pharmacy@linkmarketservices.eu through their bank or stockbroker (the "**intermediary**").

Notification for registration can take place as from **Friday, 18 April 2025** until **Thursday, 8 May 2025 at 18.00 CEST** at the latest. For this purpose, the intermediary that has registered the shares must, no later than **Friday, 9 May at 12.00 CEST**, issue a written statement in either in English or in German to Better Orange IR & HV AG by email redcare-pharmacy@linkmarketservices.eu that the shares were registered in the name of the holder thereof **on the Record Date at 18:00 CEST**. Each person who registers for the general meeting is requested to:

- include all required details to enable Better Orange IR & HV AG to verify in an efficient manner (i) the shareholding on the Record Date, and (ii) his or her attendance and/or voting rights; and
- specify whether they (i) will attend in-person or attend through the Virtual AGM Platform and (ii) intend on (x) appointing a proxy, (y) vote in advance or (z) vote during the meeting.

C.6. Proof of registration and identification

Persons who have timely registered in accordance with paragraph C.5 above will receive proof of registration and (in case of virtual attendance) an individual login data set for the Virtual AGM Platform from the respective intermediary that has registered his/her shares, which will also serve as proof for admission to the 2025 AGM via the Virtual AGM Platform.



C.7. Attending through the Virtual AGM Platform

Shareholders, or their representatives, as applicable, who have the right to attend the 2025 AGM via the Virtual AGM Platform, are required to identify themselves electronically by entering their individual login data set on the Virtual AGM Platform.

Further details about how to follow the meeting via the webcast via the Virtual AGM Platform will be made available on the Company's corporate website on **Thursday, 17 April 2025**, at <https://redcare-pharmacy.com> in the section Investor Relations/Corporate Governance/Annual General Meeting 2025.

Login for admission to the virtual meeting will take place on the day of the meeting from 09:00 CEST on Thursday, 15 May 2025.

C.8 Attending in-person

Shareholders, or their representatives, as applicable, who have the right to attend the 2025 AGM in person, must register themselves at the registration desk at the venue in Tegelen, municipality Venlo, between 09:00 CEST and the start of the annual general meeting at 10:00 CEST on Thursday, 15 May 2025. It is not possible to register or enter the meeting after this time. Shareholders and proxy holders can be asked to identify themselves when attending the 2025 AGM and can be declined access in case a satisfactory proof of identity or proof of registration lacks. All attendees of the 2025 AGM are therefore kindly requested to bring a valid identity document (i.e. passport, driving license, or identity card) with them.

C.9. Voting during the 2025 AGM

Shareholders who wish to vote during the 2025 AGM can only cast their votes through the Virtual AGM Platform. This applies to both shareholders who have chosen to attend the meeting in person and to shareholders who have chosen to participate virtually.

Shareholders who wish to attend in person and vote during the meeting should therefore ensure to be in possession of their individual login data set for the Virtual AGM Platform. The Company will provide laptops to shareholders attending the 2025 AGM in person who wish to vote during the meeting.



C.10. Proxy voting and voting instructions

Without prejudice to the provisions above regarding registration and attendance of the meeting, shareholders who are entitled to attend the 2025 AGM and choose to be represented may, in addition to the registering for the 2025 AGM in accordance with paragraph C.5, authorise others by means of a written proxy to attend:

- the virtual meeting and vote on their behalf by giving:
 - a) the respective intermediary (with the right of substitution), that has registered their shares, a proxy with voting instructions to represent them at the 2025 AGM and to vote on their behalf in the manner prescribed by that intermediary; or
 - b) Better Orange IR & HV AG an electronic proxy with voting instructions to represent them at the 2025 AGM via the Virtual AGM Platform and to vote on their behalf. In respect of this option (b), shareholders who wish to issue an electronic proxy with voting instructions must (i) login onto the Virtual AGM Platform by entering their individual login data set, and (ii) complete and duly submit the respective electronic form which will be available via the Virtual AGM Platform and accessible via the Company's corporate website from **Thursday, 17 April 2025**, at <https://redcare-pharmacy.com> in the section Investor Relations/Corporate Governance/Annual General Meeting 2025 (click [here](#)). The completed and duly submitted electronic form by the shareholder must have been received by Better Orange IR & HV AG via the Virtual AGM Platform ultimately by **Friday, 9 May at 18.00 CEST**; or
- the meeting in person and vote on their behalf by giving: (a) a third party; or (b) Better Orange IR & HV AG, a duly signed proxy with voting instructions to represent them at the 2025 AGM at the venue in Tegelen, municipality Venlo, and to vote on their behalf. In respect of both options, shareholders who wish to issue a proxy are required to use the respective form which will be available for download on the Company's website from **Thursday, 17 April 2025**, via <https://redcare-pharmacy.com> in the section Investor Relations/Corporate Governance/Annual General Meeting 2025 (click [here](#)). The completed and duly signed form by the shareholder must have been received by Better Orange IR & HV AG ultimately by **Friday, 9 May at 18.00 CEST**, by email redcare-pharmacy@linkmarketservices.eu. Before the meeting, the proxy holder must hand in a valid copy of the duly signed proxy at the registration desk.

C.11. Submission of questions

Questions can be submitted in advance of the 2025 AGM via the Virtual AGM Platform until **Thursday, 8 May 2025 at 18.00 CEST**. During the meeting, it will also be possible to raise questions, in person for those participants attending the meeting physically or via the Virtual AGM Platform for those participants attending the meeting virtually.



To submit questions via the Virtual AGM Platform, shareholders who are entitled to attend the 2025 AGM pursuant to the above provisions and timely registered as virtual attendee, must (i) login onto the Virtual AGM Platform by entering their individual login data set, and (ii) submit their questions by using the “Questions” function via the Virtual AGM Platform.

C.12. Issued share capital and voting rights of the Company

At the date of the notice convening the 2025 AGM, the Company's issued share capital amounted to EUR 411,567.82 consisting of 20,578,391 shares in bearer form having a nominal value of EUR 0.02 each. The number of shares on which voting rights can be exercised as at the day on which the 2025 AGM is convened, is 20,578,391.

* * * * *